Back to Browse Journals » Biologics: Targets and Therapy » Volume 6

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure

Authors Kekow J, Mueller-Ladner U, Schulze-Koops H

Published Date July 2012 Volume 2012:6 Pages 191—199

DOI http://dx.doi.org/10.2147/BTT.S32244

Received 26 March 2012, Accepted 17 April 2012, Published 2 July 2012

Joern Kekow,1 Ulf Mueller-Ladner,2 Hendrik Schulze-Koops3

1Clinic of Rheumatology and Orthopedics, Otto-von-Guericke University of Magdeburg, Vogelsang-Gommern; 2Department of Rheumatology and Clinical Immunology, Kerckhoff Clinic, Bad Nauheim; 3Division of Rheumatology, University of Munich, Munich, Germany

Purpose: To assess the efficacy of one course of rituximab (two 1-g doses) compared to an alternative tumor necrosis factor-α (TNFα) blocker in rheumatoid arthritis patients who had experienced one previous TNFα blocker failure (eg, etanercept, adalimumab, or infliximab).
Patients and methods: The efficacy of both treatments was studied in this retrospective, multicenter, noninterventional cohort study with 196 patients. All patients had active rheumatoid arthritis defined by a Disease Activity Score-28 of ≥3.2 despite having TNFα blocker therapy, and were followed over 6.6 months on average after switching to rituximab versus a second TNFα blocker (ie, switching to etanercept, adalimumab, or infliximab) at baseline.
Results: At baseline, both cohorts showed similar demographic and disease-related characteristics (including Disease Activity Score-28). At the end of observation, mean Disease Activity Score-28 was significantly lower after treatment with rituximab than with a second TNFα blocker (-1.64 [95% confidence interval: -1.92; -1.36] versus -1.19 [95% confidence interval: -1.42; -0.96], P = 0.013). This difference between the two groups was even more pronounced when patients were seropositive for rheumatoid factor (-1.66 versus -1.17, P = 0.018) and anti-cyclic citrullinated peptide antibodies (-1.75 versus -1.06, P = 0.002). More rituximab-treated patients achieved good European League Against Rheumatism response than TNFα blocker-treated patients (30% versus 15%), and less patients were nonresponders (22% versus 35%) according to European League Against Rheumatism criteria (P = 0.022, chi-squared test).
Conclusion: Treatment with rituximab was more effective than a second TNFα blocker therapy in rheumatoid arthritis patients after failure of the first TNFα blocker. It was found that anti-cyclic citrullinated peptide antibodies may be a useful predictive biomarker for response to rituximab in patients with TNFα blocker treatment failure.

Keywords: rheumatoid arthritis, rituximab, anti-cyclic citrullinated peptide antibodies, rheumatoid factor

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

The therapeutic potential of RORγ modulators in the treatment of human disease

Chang MR, Goswami D, Mercer BA, Griffin PR

Journal of Experimental Pharmacology 2012, 4:141-148

Published Date: 12 October 2012

Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus

Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C

Journal of Experimental Pharmacology 2012, 4:149-155

Published Date: 23 October 2012

Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review

Colucci L, Bosco M, Ziello AR, Rea R, Amenta F, Fasanaro AM

Journal of Experimental Pharmacology 2012, 4:163-172

Published Date: 12 December 2012

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

Ansari J, Hussain SA, Ansari A, Glaholm J

Biologics: Targets and Therapy 2013, 7:39-46

Published Date: 28 February 2013

Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis

Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F

Biologics: Targets and Therapy 2013, 7:69-75

Published Date: 15 March 2013

Bosutinib in the management of chronic myelogenous leukemia

Keller-von Amsberg G, Schafhausen P

Biologics: Targets and Therapy 2013, 7:115-122

Published Date: 6 May 2013